• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15F-12B filed by Calliditas Therapeutics AB

    9/23/24 4:44:35 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email
    15F-12B 1 tm2424569d1_15f12b.htm 15F-12B

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 15F

     

     

     

    CERTIFICATION OF A FOREIGN PRIVATE ISSUER’S TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 001-39308

     

     

     

    CALLIDITAS THERAPEUTICS AB

    (Exact name of registrant as specified in its charter)

     

     

     

    Kungsbron 1, D5

    SE-111 22 Stockholm, Sweden

    Tel: +46 (0) 8 411 3005

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    American Depositary Shares,

    each representing two Common Shares, quota value SEK 0.04 per share

     

    Common Shares, quota value SEK 0.04 per share*

    (Title of each class of securities covered by this Form)

     

     * Not for trading, but only in connection with the registration of the American Depositary Shares. Securities registered or to be registered pursuant to Section 12(g) of the Act.

     

    Place an X in the appropriate box(es) to indicate the provision(s) relied upon to terminate the duty to file reports under the Securities Exchange Act of 1934:

     

    Rule 12h-6(a) x   Rule 12h-6(d) ¨
    (for equity securities)   (for successor registrants)
       
    Rule 12h-6(c) ¨   Rule 12h-6(i) ¨
    (for debt securities)   (for prior Form 15 filers)

     

     

     

     

     

     

    PART I

     

    Item 1. Exchange Act Reporting History

     

    A. Calliditas Therapeutics AB (the “Company”) first incurred the duty to file reports under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on June 4, 2020, the date that the Company’s Registration Statement was declared effective by the Securities and Exchange Commission (the “Commission”). Prior to September 23, 2024, the Company’s American Depositary Shares (“ADSs”), each representing two common shares of the Company, quota value SEK 0.04 per share (the “Common Shares”), were listed on The Nasdaq Global Select Market (“Nasdaq”). On September 13, 2024, the Company voluntarily filed a Form 25 with the Commission informing the Commission that the Company had determined to voluntarily delist the ADSs from listing on Nasdaq.

     

    B. The Company has filed or submitted all reports required under Section 13(a) or Section 15(d) of the Exchange Act and the corresponding Commission rules for the 12 months preceding the filing of this Form 15F. The Company has filed at least one annual report under Section 13(a) of the Exchange Act.

     

    Item 2. Recent United States Market Activity

     

    The Company’s securities were last sold in the United States in a registered offering under the Securities Act of 1933, as amended, that was completed on June 9, 2020. On September 13, 2024, the Company filed amendments to its Registration Statement on Form F-3 (333-265881) and its two Registration Statements on Form S-8 (Nos. 333-240126 and 333-272594) to deregister any securities that remain unsold thereon, which amendments became effective upon filing.

     

    Item 3. Foreign Listing and Primary Trading Market

     

    A. The Common Shares trade under the symbol “CALTX” on the Nasdaq Stockholm stock exchange, which constitutes the primary trading market for such securities.
       
    B. The Common Shares were initially listed for trading on the Nasdaq Stockholm stock exchange on June 29, 2018, which listing has been maintained in excess of 12 months preceding the filing of this form.
       
    C. Approximately 58.3% of trading in the Common Shares and ADSs, considered as a single class of securities, occurred on Nasdaq Stockholm, and 37.0% of trading occurred in transactions outside of Nasdaq Stockholm in jurisdictions other than the United States during the 12 months preceding the filing of this form. The total trading volume that occurred outside the United States during the 12 months preceding the filing of this form is therefore greater than 95%.

     

    Item 4. Comparative Trading Volume Data

     

    The Company’s trading volume data used to rely on Rule 12h-6(a)(4)(i) are as follows:

     

    A. The recent 12-month period used to meet the requirements of Rule 12h-6(a)(4)(i) is September 5, 2023 to September 4, 2024.

     

    B. During the 12-month period beginning September 5, 2023 and ending September 4, 2024, the average daily trading volume of the ADSs in the United States was 24,038 shares and the average daily trading volume of the Common Shares and ADSs, considered as a single class of securities, on a worldwide basis was 522,866 shares.

     

    C. During the 12-month period beginning September 5, 2023 and ending September 4, 2024, the average daily trading volume of the ADSs in the United States represented 4.6% of the average daily trading volume of the Common Shares and ADSs, considered as a single class of securities, on a worldwide basis.

     

    D. On September 13, 2024, the Company filed a Form 25 with the Commission to delist its ADSs from the Nasdaq Global Select Market. At such time, for the preceding 12-month period, the average daily trading volume of the ADSs in the United States represented 4.6% of the average daily trading volume of the Common Shares and ADSs, considered as a single class of securities, on a worldwide basis.

     

    E. On September 2, 2024, the Company notified Citibank, N.A. that it intends to terminate its ADS facility. At such time, for the preceding 12-month period, the average daily trading volume of the ADSs in the United States represented 4.6% of the average daily trading volume of the Common Shares and ADSs, considered as a single class of securities, on a worldwide basis.

     

    F. The Company used trading data from the Nasdaq Stockholm, The Nasdaq Stock Market and FactSet to determine whether it meets the requirements of Rule 12h-6. The Company used the sources for trading volume information that it viewed as likely to have reliable information.

     

    Item 5. Alternative Record Holder Information

     

    Not applicable.

     

    Item 6. Debt Securities

     

    Not applicable. 

     

     

     

    Item 7. Notice Requirement

     

    A. As required by Rule 12h-6(h), the Company published a notice disclosing its intent to terminate its duty to file reports under section 13(a) and section 15(d) of the Exchange Act by means of a press release on September 3, 2024.

     

    B. The notice was disseminated in the United States via press release and was also published on the Company’s website and filed as Exhibit 99.1 to the Form 6-K filed by the Company on September 3, 2024.

     

    Item 8. Prior Form 15 Filers

     

    Not applicable.

     

    PART II

     

    Item 9. Rule 12g3-2(b) Exemption

     

    The Company has published the information required by Rule 12g3-2(b)(1)(iii) on its Internet Web site at: https://www.calliditas.se/en/.

     

    PART III

     

    Item 10. Exhibits

     

    The press release issued by the Company on September 3, 2024 is incorporated herein by reference to Exhibit 99.1 of the Form 6-K filed by the Company on September 3, 2024.

     

    Item 11. Undertakings

     

    The undersigned issuer hereby undertakes to withdraw this Form 15F if, at any time before the effectiveness of its termination of reporting under Rule 12h-6, it has actual knowledge of information that causes it reasonably to believe that, at the time of filing the Form 15F:

     

      (1) The average daily trading volume of its subject class of securities in the United States exceeded 5 percent of the average daily trading volume of that class of securities on a worldwide basis for the same recent 12-month period that the issuer used for purposes of Rule 12h-6(a)(4)(i);
         
      (2) Its subject class of securities was held of record by 300 or more United States residents or 300 or more persons worldwide, if proceeding under Rule 12h-6(a)(4)(ii) or Rule 12h-6(c); or

     

      (3) It otherwise did not qualify for termination of its Exchange Act reporting obligations under Rule 12h-6. 

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Calliditas Therapeutics AB has duly authorized the undersigned person to sign on its behalf this certification on Form 15F. In so doing, Calliditas Therapeutics AB certifies that, as represented on this Form, it has complied with all of the conditions set forth in Rule 12h-6 for terminating its registration under Section 12(g) of the Exchange Act, or its duty to file reports under Section 13(a) or Section 15(d) of the Exchange Act, or both.

     

    Date: September 23, 2024

     

      CALLITIDAS THERAPEUTCS AB
         
      By: /s/ Renée Aguiar-Lucander
      Name: Renée Aguiar-Lucander
      Title: Chief Executive Officer 

     

     

     

     


    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Press release, dated September 3, 2024 (incorporated by reference to Exhibit 99.1 of the Form 6-K filed by the Company on September 3, 2024).

     

     

     

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT

    DatePrice TargetRatingAnalyst
    6/20/2023$60.00Buy
    H.C. Wainwright
    3/1/2023$18.00Neutral
    Guggenheim
    12/20/2021$52.00 → $62.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calliditas Therapeutics AB with a new price target

      H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $60.00

      6/20/23 7:20:21 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Calliditas Therapeutics AB with a new price target

      Guggenheim initiated coverage of Calliditas Therapeutics AB with a rating of Neutral and set a new price target of $18.00

      3/1/23 6:14:34 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Calliditas Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Calliditas Therapeutics with a rating of Buy and set a new price target of $62.00 from $52.00 previously

      12/20/21 6:22:01 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

      Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/20/21 3:40:41 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Financials

    Live finance-specific insights

    See more
    • Calliditas Interim Report January to June 2024

      STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog

      8/13/24 1:22:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invitation to the presentation of Calliditas's interim report January - June 2024

      STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel

      8/5/24 1:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2023. Allocation of profit or loss                                            

      6/17/24 12:01:00 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Calliditas Therapeutics AB

      15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)

      9/23/24 4:44:35 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Calliditas Therapeutics AB

      25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)

      9/20/24 4:45:11 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

      SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/18/24 9:02:28 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/23/24 7:32:15 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/17/24 7:55:03 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB

      SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/11/24 7:42:16 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

      STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: [email protected] The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in

      9/16/24 9:46:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire

      9/3/24 7:13:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light

      9/3/24 6:31:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Calliditas Therapeutics appoints Maria Törnsén as President North America

      STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO. Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she serv

      1/7/24 11:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

      FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.       Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has

      3/22/22 8:02:00 AM ET
      $CALT
      $PHAT
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care